Events

2017 ARIZONA ALZHEIMER’S CONFERENCE SCIENTIFIC CONFERENCE

May 18, 2017

 

 

NeuroTech Conference – San Francisco

Eyal Baror will speech in this conference - Wednesday, May 31 10:40 - Treatments for Alzheimer's and Cognitive Disorders
Globally, the population continues to age and the number of dementia patients keeps expanding. Ongoing efforts to develop disease modifying therapies have been plagued with failures. What new avenues are being pursued to address the growing global need? Will novel diagnostics allow us to initiate treatments earlier? What non-pharmacological options are in development?
Panelists: Casey Lynch, CEO, Cortexyme
Mark Gurney, CEO, Tetra Discovery Partners
Eyal Baror, CEO and President, Neuronix

31st May – 1st June 2017

 

 

Alzheimer’s London - Alzheimer’s Manchester

London
Stand: E3 Neuronix manufactures and markets the NeuroAD System, an innovative, non-invasive, medical device for the treatment of Alzheimer’s. NeuroAD is the only non-pharmaceutical, CE-approved treatment in the UK that has been proven to improve cognitive function and help regain lost skills, with no side effects. With Neuronix, impacting Alzheimer’s is possible

Manchester
Stand: B7 Neuronix manufactures and markets the NeuroAD System, an innovative, non-invasive, medical device for the treatment of Alzheimer’s. NeuroAD is the only non-pharmaceutical, CE-approved treatment in the UK that has been proven to improve cognitive function and help regain lost skills, with no side effects. With Neuronix, impacting Alzheimer’s is possible.

June 9-10, 2017  |  June 23-24, 2017

 

 

 

Past Events

CTAD conference in San Diego December 8-10.2016

December 8-10, 2016

 

 

Braintech 2017 : March 6-7, Tel-Aviv Israel

March 6-7, 2017

 

 

ADPD – Vienna – Austria - Dr. Babak Tousi - EFFECTS OF A COMBINED TRANSCRANIAL MAGNETIC STIMULATION (TMS) AND COGNITIVE TRAINING IN ALZHEIMER PATIENTS: SAFETY RESULTS OF MEDICAL DEVICE PIVOTAL MULTI-CENTER STUDY

 

March 29th – April 2nd 2017

 

 

AD/PD – Vienna

March 29th – April 2nd 2017

neuroAD is an investigational device currently not commercially available in the United States.
neuroAD is CE-cleared and commercially available for the treatment of mild to moderate Alzheimer’s Disease in Europe.



® August 3, 2017 Neuronix | All rights reserved.
a site by razgroup